- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02446600
Testen der Verwendung eines einzelnen Medikaments (Olaparib) oder der Kombination zweier Medikamente (Cediranib und Olaparib) im Vergleich zur üblichen Chemotherapie bei Frauen mit platinempfindlichem Eierstock-, Eileiter- oder primärem Bauchfellkrebs
Eine Phase-III-Studie zum Vergleich der Monotherapie mit Olaparib oder der Kombination von Cediranib und Olaparib mit einer Standard-Chemotherapie auf Platinbasis bei Frauen mit rezidivierendem platinsensitivem Ovarial-, Eileiter- oder primärem Peritonealkrebs
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Studienübersicht
Status
Bedingungen
- Rezidivierendes Eileiterkarzinom
- Rezidivierendes Ovarialkarzinom
- Rezidivierendes primäres Peritonealkarzinom
- Ovariales seromuzinöses Karzinom
- Ovariales undifferenziertes Karzinom
- Klarzelliges Adenokarzinom der Eierstöcke
- Übergangszellkarzinom des Eileiters
- Eierstock-Übergangszellkarzinom
- Klarzelliges Adenokarzinom des Eileiters
- Eileiter undifferenziertes Karzinom
- Rezidivierendes endometrioides Adenokarzinom der Eierstöcke
- Ovarialer endometrioider Tumor
- Seröser Eierstocktumor
Intervention / Behandlung
- Arzneimittel: Carboplatin
- Arzneimittel: Paclitaxel
- Sonstiges: Laboratory Biomarker Analysis
- Sonstiges: Quality-of-Life Assessment
- Verfahren: Biospecimen Collection
- Verfahren: Computed Tomography
- Verfahren: Magnetic Resonance Imaging
- Verfahren: Echocardiography Test
- Verfahren: Multigated Acquisition Scan
- Sonstiges: Pharmacological Study
- Arzneimittel: Gemcitabine Hydrochloride
- Arzneimittel: Cediranib Maleate
- Arzneimittel: Olaparib
- Arzneimittel: Gemcitabine
- Arzneimittel: Pegylated Liposomal Doxorubicin Hydrochloride
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
SECONDARY OBJECTIVES:
I. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by response rate and overall survival as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
II. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, in women with or without deleterious germline breast cancer (BRCA) mutations (gBRCAmt) in the setting of recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
III. Assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18), of single agent olaparib or cediranib and olaparib, compared to standard platinum-based chemotherapy, in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.
IV. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, in women with or without homologous repair deficiencies as measured by BROCA in the setting of recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
V. To assess changes in the number of circulating endothelial cells (CECs) following three days of treatment with olaparib, combination olaparib/cediranib, or standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
VI. To assess whether change in the number of circulating endothelial cells (CECs) following three days of treatment with olaparib, combination olaparib/cediranib, or standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer is prognostic for PFS.
VII. To develop a profile from a panel of angiogenic biomarkers in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer which is associated with PFS, and then validate the predictive value of this biomarker profile.
EXPLORATORY OBJECTIVES:
I. To assess the time from randomization to the first non-study, anti-cancer therapy, surgery or death (TFST) for single-agent olaparib or combination cediranib and olaparib relative to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
II. To assess the time from randomization to the second non-study, anti-cancer therapy, surgery or death (TSST) for single-agent olaparib or combination cediranib and olaparib relative to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
III. Assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/Gynecologic Oncology Group-Neurotoxicity version 4 (GOG-Ntx-4), and health utility as measured by the Euro Quality of Life-5 Dimension (EQ-5D), of single agent olaparib or cediranib and olaparib, compared to standard platinum-based chemotherapy, in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients may be treated with one of the three regimens per investigator discretion.
REGIMEN I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes and on day 1. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) as well as blood sample collection throughout the trial.
REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes and on day 1. Treatment repeats every 28 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
ARM II: Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
ARM III: Patients receive olaparib PO BID and cediranib maleate PO once daily (QD). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Saitama, Japan, 350-1298
- Saitama Medical University International Medical Center
-
Tokyo, Japan, 104 0045
- National Cancer Center Hospital
-
-
Iwate
-
Shiwa-gun, Iwate, Japan, 028-3695
- Iwate Medical University Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japan, 890-8760
- Kagoshima City Hospital
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital Of JFCR
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
London, Ontario, Kanada, N6A 4L6
- London Regional Cancer Program
-
Ottawa, Ontario, Kanada, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Sault Ste. Marie, Ontario, Kanada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Kanada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
Montreal, Quebec, Kanada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Québec, Quebec, Kanada, G1R 2J6
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
-
-
-
Seoul, Südkorea, 110-744
- Seoul National University Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Vereinigte Staaten, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85704
- Arizona Oncology Associates-West Orange Grove
-
Tucson, Arizona, Vereinigte Staaten, 85710
- Arizona Oncology Associates-Wilmot
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Arroyo Grande, California, Vereinigte Staaten, 93420
- PCR Oncology
-
Carmichael, California, Vereinigte Staaten, 95608
- Mercy San Juan Medical Center
-
Greenbrae, California, Vereinigte Staaten, 94904
- Marin Cancer Care Inc
-
La Jolla, California, Vereinigte Staaten, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars-Sinai Medical Center
-
Mountain View, California, Vereinigte Staaten, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Vereinigte Staaten, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Vereinigte Staaten, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Vereinigte Staaten, 95825
- Kaiser Permanente Sacramento Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Mercy Cancer Center - Sacramento
-
San Francisco, California, Vereinigte Staaten, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Vereinigte Staaten, 94115
- California Pacific Medical Center-Pacific Campus
-
San Luis Obispo, California, Vereinigte Staaten, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Clara, California, Vereinigte Staaten, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Cruz, California, Vereinigte Staaten, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Vereinigte Staaten, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Vereinigte Staaten, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Kaiser Permanente-Walnut Creek
-
Woodland, California, Vereinigte Staaten, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Vereinigte Staaten, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, Vereinigte Staaten, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Vereinigte Staaten, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, Vereinigte Staaten, 80205
- Kaiser Permanente-Franklin
-
Denver, Colorado, Vereinigte Staaten, 80220
- Rocky Mountain Cancer Centers-Rose
-
Fort Collins, Colorado, Vereinigte Staaten, 80524
- Poudre Valley Hospital
-
Lafayette, Colorado, Vereinigte Staaten, 80026
- Kaiser Permanente-Rock Creek
-
Littleton, Colorado, Vereinigte Staaten, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Kaiser Permanente-Lone Tree
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Wheat Ridge, Colorado, Vereinigte Staaten, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Fairfield, Connecticut, Vereinigte Staaten, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Hartford, Connecticut, Vereinigte Staaten, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Vereinigte Staaten, 06102
- Hartford Hospital
-
Middletown, Connecticut, Vereinigte Staaten, 06457
- Middlesex Hospital
-
New Britain, Connecticut, Vereinigte Staaten, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
Torrington, Connecticut, Vereinigte Staaten, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Vereinigte Staaten, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Vereinigte Staaten, 19971
- Beebe Health Campus
-
Seaford, Delaware, Vereinigte Staaten, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- UF Health Cancer Institute - Gainesville
-
-
Georgia
-
Athens, Georgia, Vereinigte Staaten, 30607
- University Cancer and Blood Center LLC
-
Atlanta, Georgia, Vereinigte Staaten, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Northside Hospital
-
Decatur, Georgia, Vereinigte Staaten, 30033
- Emory Decatur Hospital
-
Macon, Georgia, Vereinigte Staaten, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
-
Illinois
-
Aurora, Illinois, Vereinigte Staaten, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Vereinigte Staaten, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University
-
Chicago, Illinois, Vereinigte Staaten, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Vereinigte Staaten, 60657
- UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Vereinigte Staaten, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Vereinigte Staaten, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Illinois CancerCare-Macomb
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Vereinigte Staaten, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Springfield Memorial Hospital
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- University of Kansas Cancer Center
-
Pittsburg, Kansas, Vereinigte Staaten, 66762
- Mercy Hospital Pittsburg
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Associates In Womens Health
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Vereinigte Staaten, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Vereinigte Staaten, 40207
- Norton Suburban Hospital and Medical Campus
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70817
- Woman's Hospital
-
Covington, Louisiana, Vereinigte Staaten, 70433
- Women's Cancer Care-Covington
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Brewer, Maine, Vereinigte Staaten, 04412
- Lafayette Family Cancer Center-EMMC
-
Scarborough, Maine, Vereinigte Staaten, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Vereinigte Staaten, 21204
- Greater Baltimore Medical Center
-
Easton, Maryland, Vereinigte Staaten, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Tufts Medical Center
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Clinic
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brownstown, Michigan, Vereinigte Staaten, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Escanaba, Michigan, Vereinigte Staaten, 49829
- OSF Saint Francis Hospital and Medical Group
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Hurley Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Vereinigte Staaten, 48912
- University of Michigan Health - Sparrow Lansing
-
Manistique, Michigan, Vereinigte Staaten, 49854
- Schoolcraft Memorial Hospital
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Southfield, Michigan, Vereinigte Staaten, 48075
- Henry Ford Health Providence Southfield Hospital
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Henry Ford West Bloomfield Hospital
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy Hospital
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Mankato, Minnesota, Vereinigte Staaten, 56001
- Mayo Clinic Health Systems-Mankato
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Shakopee, Minnesota, Vereinigte Staaten, 55379
- Saint Francis Regional Medical Center
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- Saint Dominic-Jackson Memorial Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Mercy Hospital Joplin
-
Springfield, Missouri, Vereinigte Staaten, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Barnes-Jewish Hospital
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Vereinigte Staaten, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Vereinigte Staaten, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Vereinigte Staaten, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Vereinigte Staaten, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Alegent Health Lakeside Hospital
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89106
- Women's Cancer Center of Nevada
-
-
New Hampshire
-
Dover, New Hampshire, Vereinigte Staaten, 03820
- Wentworth-Douglass Hospital
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Nashua, New Hampshire, Vereinigte Staaten, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Basking Ridge, New Jersey, Vereinigte Staaten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Cooper Hospital University Medical Center
-
Englewood, New Jersey, Vereinigte Staaten, 07631
- Englewood Hospital and Medical Center
-
Voorhees Township, New Jersey, Vereinigte Staaten, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Vereinigte Staaten, 88011
- Memorial Medical Center-Las Cruces
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Vereinigte Staaten, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Vereinigte Staaten, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
The Bronx, New York, Vereinigte Staaten, 10461
- Montefiore Medical Center-Einstein Campus
-
Uniondale, New York, Vereinigte Staaten, 11553
- Memorial Sloan Kettering Nassau
-
White Plains, New York, Vereinigte Staaten, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Pinehurst, North Carolina, Vereinigte Staaten, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Raleigh, North Carolina, Vereinigte Staaten, 27609
- Duke Cancer Center Raleigh
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
Minot, North Dakota, Vereinigte Staaten, 58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, Vereinigte Staaten, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Vereinigte Staaten, 44122
- UHHS-Chagrin Highlands Medical Center
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Vereinigte Staaten, 45247
- TriHealth Cancer Institute-Westside
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Vereinigte Staaten, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Vereinigte Staaten, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Columbus Oncology and Hematology Associates Inc
-
Dayton, Ohio, Vereinigte Staaten, 45405
- Grandview Hospital
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Orion Cancer Care
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Vereinigte Staaten, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania, Ohio, Vereinigte Staaten, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Vereinigte Staaten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Wadsworth, Ohio, Vereinigte Staaten, 44281
- University Hospitals Sharon Health Center
-
Westlake, Ohio, Vereinigte Staaten, 44145
- UHHS-Westlake Medical Center
-
Wright-Patterson Air Force Base, Ohio, Vereinigte Staaten, 45433
- Wright-Patterson Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Vereinigte Staaten, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Vereinigte Staaten, 97701
- Saint Charles Health System
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Willamette Valley Cancer Center
-
Gresham, Oregon, Vereinigte Staaten, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Vereinigte Staaten, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Abington, Pennsylvania, Vereinigte Staaten, 19001
- Jefferson Abington Hospital
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Vereinigte Staaten, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Vereinigte Staaten, 17325
- Adams Cancer Center
-
Lancaster, Pennsylvania, Vereinigte Staaten, 17602
- Lancaster General Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
Sayre, Pennsylvania, Vereinigte Staaten, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Selinsgrove, Pennsylvania, Vereinigte Staaten, 17870
- Geisinger Medical Oncology-Selinsgrove
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Reading Hospital
-
Williamsport, Pennsylvania, Vereinigte Staaten, 17701
- UPMC Susquehanna
-
York, Pennsylvania, Vereinigte Staaten, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- AnMed Health Cancer Center
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
Gaffney, South Carolina, Vereinigte Staaten, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Vereinigte Staaten, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, Vereinigte Staaten, 29926-3827
- South Carolina Cancer Specialists PC
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Vereinigte Staaten, 29379
- SMC Center for Hematology Oncology Union
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Johnson City, Tennessee, Vereinigte Staaten, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Vereinigte Staaten, 37932
- Covenant Health Cancer Centers - West
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78731
- Texas Oncology - Central Austin Cancer Center
-
Austin, Texas, Vereinigte Staaten, 78745
- Texas Oncology - South Austin Cancer Center
-
Bedford, Texas, Vereinigte Staaten, 76022
- Texas Oncology Bedford
-
Dallas, Texas, Vereinigte Staaten, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Texas Oncology - Fort Worth Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Houston Methodist Hospital
-
Houston, Texas, Vereinigte Staaten, 77070
- Methodist Willowbrook Hospital
-
Sugar Land, Texas, Vereinigte Staaten, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- Texas Oncology-The Woodlands
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84107
- Intermountain Medical Center
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Utah Cancer Specialists-Salt Lake City
-
St. George, Utah, Vereinigte Staaten, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Kennewick, Washington, Vereinigte Staaten, 99336
- Kadlec Clinic Hematology and Oncology
-
Mount Vernon, Washington, Vereinigte Staaten, 98274
- Skagit Valley Hospital
-
Mount Vernon, Washington, Vereinigte Staaten, 98274
- Skagit Regional Health Cancer Care Center
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Vereinigte Staaten, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Vereinigte Staaten, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Vereinigte Staaten, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Vereinigte Staaten, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Vereinigte Staaten, 98133
- Women's Cancer Center of Seattle
-
Vancouver, Washington, Vereinigte Staaten, 98686
- Legacy Salmon Creek Hospital
-
Wenatchee, Washington, Vereinigte Staaten, 98801
- Wenatchee Valley Hospital and Clinics
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Edwards Comprehensive Cancer Center
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Vereinigte Staaten, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Vereinigte Staaten, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Saint Vincent Hospital Cancer Center at Marinette
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Vereinigte Staaten, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54481
- Aspirus Cancer Care - Stevens Point
-
Sturgeon Bay, Wisconsin, Vereinigte Staaten, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Vereinigte Staaten, 54401
- Marshfield Clinic-Wausau Center
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Vereinigte Staaten, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers; patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-risk histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory; Note: Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing will be accepted; if testing for germline BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germline deleterious BRCA1 or BRCA2 mutation or BRCA rearrangement is required; please collect a copy of Myriad or other BRCA mutational analysis (positive or VUS or negative) reports
- Platinum-sensitive disease defined as no clinical or radiographic evidence of disease recurrence for > 6 months (or 182 days) after last receipt of platinum-based therapy
- Patients must have had a complete clinical response to their prior line of platinum therapy and cannot have had progression through prior platinum-based therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
-
Patients must have evaluable disease - defined as one of the following:
- Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR
- Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)
-
Prior therapy:
- Prior chemotherapy must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy
- Patients may have received an unlimited number of platinum-based therapies in the recurrent setting
- Patients may have received up to 1 non-platinum-based line of therapy in the recurrent setting; prior hormonal therapy will not be considered to count as this non-platinum-based line
- Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed
- Patients may not have previously received a poly adenosine diphosphate (ADP) ribose polymerase (PARP)-inhibitor
- Prior hormonal-based therapy for ovarian, primary peritoneal, or fallopian tube cancer is acceptable
-
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Karnofsky >= 60%)
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Hemoglobin >= 10 g/dL
-
Creatinine =< the institutional upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Urine protein: creatinine ratio (UPC) of =< 1 or less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with >= 2+ proteinuria on dipstick must also have a 24 hour urine collection demonstrating =< 500 mg over 24 hours
-
Total bilirubin =< 1.5 x the institutional ULN
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 times institutional ULN
-
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE); patients with long-standing stable grade 2 neuropathy may be considered after discussion with the overall principal investigator (PI), but may not receive carboplatin and paclitaxel as the reference regimen, if randomized to that arm
-
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
-
Patients must have adequately controlled blood pressure (BP), with a BP no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocol
-
Patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to Arm III
-
Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
-
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid stimulating hormone (TSH) within normal limits
-
Age >= 18
Exclusion Criteria:
-
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions
-
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
-
Patients may not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
-
Patients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway (including, but not limited to thalidomide, sunitinib, pazopanib, sorafenib, and nintedanib); bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed
-
Patients may not have previously received a PARP inhibitor
-
CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease
-
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on CT or MRI scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; screening imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
-
Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; strong inhibitors and inducers of UGT/PgP should be used with caution
-
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula
-
History of intra-abdominal abscess within the past 3 months
-
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs
-
Dependency on intravenous (IV) hydration or total parenteral nutrition (TPN)
-
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:
- Treated limited stage basal cell or squamous cell carcinoma of the skin
- Carcinoma in situ of the breast or cervix
- Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
- Prior cancer treated with a curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence
-
Patients with any of the following:
- History of myocardial infarction within six months
- Unstable angina
- Resting electrocardiogram (ECG) with clinically significant abnormal findings
- New York Heart Association (NYHA) classification of III or IV
-
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines
-
Patients with the following risk factors should have a baseline cardiac function assessment:
- Prior treatment with anthracyclines
- Prior treatment with trastuzumab
- Prior central thoracic radiation therapy (RT), including RT to the heart
- History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)
- Prior history of impaired cardiac function
-
-
History of stroke or transient ischemic attack within six months
-
Any prior history of hypertensive crisis or hypertensive encephalopathy
-
Clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study
-
Known HIV-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
-
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
-
No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
-
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm I (platinum-based chemotherapy)
See detailed description. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Correlative studies Ancillary studies
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: Arm II (olaparib)
Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial. |
Correlative studies Ancillary studies
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Correlative studies Given PO
Andere Namen:
|
|
Experimental: Arm III (olaparib, cediranib maleate)
Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial. |
Correlative studies Ancillary studies
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Correlative studies Given PO
Andere Namen:
Given PO
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression Free Survival Determined Using Response Evaluation Criteria in Solid Tumors Version 1.1 Criteria
Zeitfenster: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. An average of approximately 10 months.
|
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Japanese cohort not included in progression free survival analysis, only included in toxicity assessments. |
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. An average of approximately 10 months.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival
Zeitfenster: Approximately 30 months
|
Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Japanese cohort not included in overall survival analysis, the cohort was only included in toxicity assessments. |
Approximately 30 months
|
|
Frequency and Severity of Adverse Effects
Zeitfenster: During treatment period and up to 100 days after stopping the study treatment, up to 39 months.
|
Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy, by Preferred term with incidence rate greater than 5%. |
During treatment period and up to 100 days after stopping the study treatment, up to 39 months.
|
|
Patient Reported Scores of Disease-related Symptoms as Measured by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 Disease-Related Symptom-Physical
Zeitfenster: Prior to cycle 1, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 and 108 weeks after starting treatment
|
Disease-related physical symptoms were measured by the Disease-Related Symptom-Physical (DRS-P) subscale of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NCCN/FOSI-18). The DRS-P subscale is composed of 9 items. For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The DRS-P score ranges 0-36 with a larger score suggesting better QOL (Quality of Life) or less symptoms. This analysis did not include the Japanese cohort. |
Prior to cycle 1, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 and 108 weeks after starting treatment
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Zeit von der Randomisierung bis zur ersten Nicht-Studie, Anti-Krebs-Behandlung oder Tod
Zeitfenster: Bis zu 5 Jahre
|
Bis zu 5 Jahre
|
|
Zeit von der Randomisierung bis zur zweiten Nichtstudie, Krebsbehandlung oder Tod
Zeitfenster: Bis zu 5 Jahre
|
Bis zu 5 Jahre
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Joyce F Liu, NRG Oncology
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
- Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 1;40(19):2138-2147. doi: 10.1200/JCO.21.02011. Epub 2022 Mar 15.
- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Genitalerkrankungen, weiblich
- Neoplasmen der endokrinen Drüse
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Eileitererkrankungen
- Eierstocktumoren
- Eileiterneoplasmen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Kohlenhydrate
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glykoside
- Koordinationskomplexe
- Taxoid
- Cyclodececane
- Diterpene
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Gesundheitsökonomie und Organisationen
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Daunorubicin
- Wirtschaft
- Gemcitabin
- Carboplatin
- Doxorubicin
- Paclitaxel
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Liposomal Doxorubicin
- Olaparib
- Cediranib
- Steuern
Andere Studien-ID-Nummern
- NCI-2015-00606
- U10CA180868 (US NIH Stipendium/Vertrag)
- NCI-2015-00606 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- s16-01480
- NRG-GY004 (Andere Kennung: CTEP)
- NRG-GY004
- NRG-GY004 (Andere Kennung: NRG Oncology)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .